Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging

Table 1 Characteristics of the patients that concluded the study

Characteristic	Value
Number of included patients	46
Age, mean (range), years	54 (33–72)
Postmenopausal, n (%)	20	43
Histological assessment, n (%)
Invasive ductal carcinoma	40	87
Invasive lobular carcinoma	4	9
Metaplastic carcinoma	2	4
TNM stage at diagnosis, n (%)
T2N0	13	28
T2N+	17	37
T3N0	5	11
T3N+	9	20
T4N+	2	4
Molecular characteristics, n (%)
Luminal A	3	6
Luminal B	16	35
Luminal B HER2+	6	13
HER2+	9	20
Triple negative	12	26
Histopathological response to NAC in surgical specimen (RECIST 1.1), n (%)
Complete response (pCR)	8	17
Partial response (pPR)	32	70
Stable disease (pSD)	5	11
Progressive disease (pPD)	1	2
Surgical treatment, n (%)
Lumpectomy	28	61
Mastectomy	18	39

HER2 human epidermal growth factor receptor 2, NAC neoadjuvant chemotherapy, RECIST response evaluation criteria in solid tumors, pCR pathological complete response, pPR pathological partial response, pSD pathological stable disease, pPD pathological progressive disease

ISSN: 1465-542X